Loading data for CUVL — first visit, this takes a few seconds.
Clinuvel Pharmaceuticals Limited (CUVL)
NasdaqGS: CUVL
· Real-Time Price · USD
6.52
+0.33 (5.33%)
At close: Sep 04, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Clinuvel Pharmaceuticals Limited (CUVL) Stock Price, Analysis & Data
No data available
| Bid | 6.9 |
| Market Cap | 329M |
| Revenue (ttm) | 94M |
| Net Income (ttm) | 33.9M |
| 0.56 | |
| 0.48 | |
| 13.58 | |
| n/a | |
| P/B (ttm) | 1.68 |
| P/S (ttm) | 3.50 |
| Earnings Date | n/a |
| Ask | 7.09 |
| Volume | 79,283 |
| Avg. Volume (20D) | 9,407 |
| Open | 6.29 |
| Previous Close | 6.19 |
| Day's Range | 6.10 - 6.73 |
| 52-Week Range | 5.95 - 8.92 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $0.04 (0.55%) |
| Ex-Dividend Date | Sep 8, 2026 |
About CUVL
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV99...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 30, 2008
Employees n/a
Stock Exchange NasdaqGS
Ticker Symbol CUVL
Website https://www.clinuvel.com
Financial Performance
In 2025, Clinuvel Pharmaceuticals's revenue was 95.02M, an increase of 7.76% compared to the previous year's 88.18M. Earnings were 36.17M, an increase of 1.5%.
Financial StatementsEarnings Surprise
Clinuvel Pharmaceuticals has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.